FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 345 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health... December 2, 2025 Bra Straps with Disappearing Message Remind Women to Check Their Breasts... April 12, 2021 A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... April 20, 2023 Load more HOT NEWS Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... BooHoo Is Selling Bras With Subtle Patterns To Help You Check... Melanoma Cells Are More Likely to Spread after a Stopover in... Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts...
